People
Selecta Biosciences announced that as part of restructuring efforts it is cutting its current workforce by 36 percent. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent.
Over the past decade, BMS has been no stranger to flexing its M&A muscle. The company made numerous focused-acquisitions that have positioned itself as a leader in oncology. BMS CEO Giovanni Caforio noted that the massive deal for Celgene is another piece to that puzzle.
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
In 2013 Pfizer launched its Dare to Try initiative, a project designed to foster internal innovation at the pharma giant. It was an effort that encouraged employees to not be afraid to fail as they reached for the sky.
Novartis and Pfizer veteran Elizabeth Barrett will take over as the new president and chief executive officer of UroGen Pharma Ltd. Barrett, who most recently helmed Novartis Oncology, will take over as Ron Bentsur steps down from his role as CEO.
Pharmaceutical companies traditionally adjust the price of drugs twice a year, so it wouldn’t normally be a hot topic. But drug prices have been a controversial subject for several years, especially in politics.
Peter Durkee Meldrum, a co-founder and the former chief executive officer of Salt Lake City, Utah-based Myriad Genetics, Inc. died Dec. 20. He was 71.
Follow-up investigations by the Wall Street Journal suggest that He Jiankui’s story may be just the tip of the iceberg of sloppy and unmonitored clinical trials using CRISPR in China.
Professor Jackie Y. Ying who heads A*STAR’s NanoBio Lab in Singapore has won the 2018 Turkish Academy of Sciences Academy Prize in Science and Engineering Sciences
Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
PRESS RELEASES